TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
NCT02141711
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Erosive Esophagitis(EE)
Gastroesophageal Reflux Disease (GERD)
Interventions
DRUG:
TAK-438
DRUG:
TAK-438 Placebo
Sponsor
Takeda